EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PO56 | EXTERNAL VALIDATION OF THE SAVED SCORE IN A CANADIAN REGIONAL CANCER CENTER COHORT: A REAL-WORLD ANALYSIS

Società Italiana di Emostasi e Trombosi

Bleeding, Thrombosis and Vascular Biology · 16.04.2026 · 5 (s1)

DOI: 10.4081/btvb.2026.548 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bleeding, Thrombosis and Vascular Biology, online erschienen am 16.04.2026. Verfasst von Società Italiana di Emostasi e Trombosi. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Venous thromboembolism (VTE) remains a significant complication in multiple myeloma patients receiving immunomodulatory drugs, with incidence rates of 3-26%. The SAVED score was developed to stratify VTE risk using readily available clinical variables. While initial validation demonstrated strong discriminatory ability in large academic centers, real-world performance in community cancer centers has not been characterized. This study aims to validate the SAVED score in a Canadian Regional Cancer Centre cohort.

Methods

We reviewed 182 multiple myeloma patients who began lenalidomide treatment between January 2013 and February 2025 at the Durham Regional Cancer Centre, with follow-up through January 2026. The SAVED score was calculated using age >80 years (+1), Asian ethnicity (-3), prior VTE (+3), surgery within 90 days (+2), and dexamethasone 120-160 mg monthly (+1) or >160 mg monthly (+2). Patients were classified as low risk (SAVED 0-1) or high risk (≥2). The main result was VTE during lenalidomide therapy, which was confirmed by imaging. Statistical analysis included the Fisher exact test, Kaplan-Meier survival analysis with the log-rank test, and ROC curve analysis. Sensitivity analyses excluded patients with prior VTE and tested alternative cutoffs (≥3).

Results

The median age was 79 years. Overall VTE rate was 12.6% (23/182). Low-risk patients (n=139, 76.4%) had a 5.8% VTE rate vs. 34.9% in high-risk patients (n=43, 23.6%). The odds ratio was 8.77 (95% CI 3.39-22.69, p

Zitieren

APA

Trombosi, S. I. D. E. E. (2026). PO56 | EXTERNAL VALIDATION OF THE SAVED SCORE IN A CANADIAN REGIONAL CANCER CENTER COHORT: A REAL-WORLD ANALYSIS. Bleeding, Thrombosis and Vascular Biology, 5(s1). https://doi.org/10.4081/btvb.2026.548

Vancouver

Trombosi SIDEE. PO56 | EXTERNAL VALIDATION OF THE SAVED SCORE IN A CANADIAN REGIONAL CANCER CENTER COHORT: A REAL-WORLD ANALYSIS. Bleeding, Thrombosis and Vascular Biology. 2026;5(s1). doi:10.4081/btvb.2026.548

BibTeX
@article{Trombosi2026,
  author = {Trombosi, Società Italiana di Emostasi e},
  title = {PO56 | EXTERNAL VALIDATION OF THE SAVED SCORE IN A CANADIAN REGIONAL CANCER CENTER COHORT: A REAL-WORLD ANALYSIS},
  journal = {Bleeding, Thrombosis and Vascular Biology},
  year = {2026},
  volume = {5},
  number = {s1},
  doi = {10.4081/btvb.2026.548}
}
Kostenlos starten →